The American Journal of Medicine
Volume 122, Issue 3 , Pages 265-272 , March 2009

B-Type Natriuretic Peptides for the Evaluation of Exercise Intolerance

  • Christian Mueller, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • Corresponding Author InformationRequests for reprints should be addressed to Christian Mueller, MD, FESC, Department of Internal Medicine, University Hospital Basel, Petersgraben 4, CH-4031 Basel, Switzerland
    • ,
  • Micha T. Maeder, MD

      Affiliations

    • Department of Cardiology, University Hospital Basel, Switzerland
    • ,
  • Andreas Christ, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Tobias Reichlin, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Daniel Staub, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Markus Noveanu, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Tobias Breidthardt, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Mihael Potocki, MD

      Affiliations

    • Department of Internal Medicine, University Hospital Basel, Switzerland
    • ,
  • Martin H. Brutsche, MD, PhD

      Affiliations

    • Division of Pulmonary Care, University Hospital Basel, Switzerland

References 

  1. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2003;167:211–277
  2. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161–167
  3. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med. 2004;350:647–654
  4. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J. 2006;27:330–337
  5. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005;95:948–954
  6. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357–2368
  7. Staub D, Jonas N, Zellweger MJ, et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med. 2005;118:1287
  8. Staub D, Nusbaumer C, Zellweger MJ, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J. 2006;151:1223–1230
  9. Schmid A, Schilter D, Fengels I, et al. Design and validation of an interpretative strategy for cardiopulmonary exercise tests. Respirology. 2007;12:916–923
  10. Guazzi M, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. J Am Coll Cardiol. 2005;46:1883–1890
  11. Robbins M, Francis G, Pashkow FJ, et al. Ventilatory and heart rate responses to exercise : better predictors of heart failure mortality than peak oxygen consumption. Circulation. 1999;100:2411–2417
  12. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Preliminary evaluation of the AxSYM B-type natriuretic peptide (BNP) assay and comparison with the ADVIA Centaur BNP assay. Clin Chem. 2004;50:1104–1106
  13. Barnes SC, Collinson PO, Galasko G, et al. Evaluation of N-terminal pro-B type natriuretic peptide analysis on the Elecsys 1010 and 2010 analysers. Ann Clin Biochem. 2004;41:459–463
  14. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 1994;343:440–444
  15. Mueller C, Breidthardt T, Laule-Kilian K, et al. The integration of BNP and NT-proBNP into clinical medicine. Swiss Med Wkly. 2007;137:4–12
  16. Martinez-Rumayor A, Richards AM, Burnett JC, Januzzi JL. Biology of the natriuretic peptides. Am J Cardiol. 2008;101:3–8
  17. Wermuth J, Staub D, Laule-Kilian K, et al. Neurohormonal activation and left ventricular ejection fraction in patients with suspected myocardial ischemia. Int J Cardiol. 2007;120:248–253
  18. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol. 2002;40:976–982
  19. O'Neill JO, Bott-Silverman CE, McRae AT, et al. B-type natriuretic peptide levels are not a surrogate marker for invasive hemodynamics during management of patients with severe heart failure. Am Heart J. 2005;149:363–369
  20. Forfia PR, Watkins SP, Rame JE, et al. Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol. 2005;45:1667–1671
  21. Tschope C, Kasner M, Westermann D, et al. Elevated NT-ProBNP levels in patients with increased left ventricular filling pressure during exercise despite preserved systolic function. J Card Fail. 2005;11:S28–S33
  22. Marie PY, Mertes PM, Hassan-Sebbag N, et al. Exercise release of cardiac natriuretic peptides is markedly enhanced when patients with coronary artery disease are treated medically by beta-blockers. J Am Coll Cardiol. 2004;43:353–359
  23. de Groote P, Soudan B, Lamblin N, et al. Is hormonal activation during exercise useful for risk stratification in patients with moderate congestive heart failure?. Am Heart J. 2004;148:349–355
  24. Barletta G, Stefani L, Del Bene R, et al. Effects of exercise on natriuretic peptides and cardiac function in man. Int J Cardiol. 1998;65:217–225
  25. Nicholson S, Richards M, Espiner E, et al. Atrial and brain natriuretic peptide response to exercise in patients with ischaemic heart disease. Clin Exp Pharmacol Physiol. 1993;20:535–540

 Funding: CM (Grant PP00B-102853) and MTM (Grant PBZHB-121007) are supported by the Swiss National Science Foundation.

 Conflicts of Interest: Dr. Mueller has received research support from Abbott, Biosite, Brahms, and Roche as well as speaker's honoraria from Abbott, Bayer, Biosite, Brahms, and Roche Diagnostic. The other authors have no possible conflicts of interest to declare. Diagnostic reagents were provided by Roche Diagnostics (Basel, Switzerland) and Abbott (Zug, Switzerland). The sponsors had no role in study design, data analysis, or interpretation.

 Authorship: All authors had access to the data and played a role in writing this manuscript.

PII: S0002-9343(08)00986-8

doi: 10.1016/j.amjmed.2008.08.030

The American Journal of Medicine
Volume 122, Issue 3 , Pages 265-272 , March 2009

Article Tools

* Image Usage & Resolution